| Metric / Component | Grade | Score | Evidence & Notes | Horizon |
|---|---|---|---|---|
| FINAL ESEN MASTER SCORE | A− | 82 | Strong hyper-growth profile (128.8% EPS YoY) offset by elevated valuation (PE 55.9x) and flagged profitability constraints. Exceptional innovation momentum in GLP-1 portfolio. | 6–12M |
| SA Quality/Value Composite | A | 85 | Quality-weighted: Low beta (0.50) signifies defensive stability. Revenue growth 47.4% YoY indicates durable demand cycle. PEG 0.43 reflects growth-adjusted affordability. | 6–12M |
| Zacks Earnings Momentum | A | 88 | EPS growth 128.8% YoY is exceptional in pharmaceuticals sector. Forward PE 27.3x significantly below current suggests consensus upside. Hyper-growth flag confirmed. | 3–6M |
| Institutional & Smart Money Flow | A− | 81 | Market cap $1.15T reflects dominant institutional ownership. Recent −0.87% pullback on strong fundamentals suggests accumulation window. 52-week return 59% validates positioning. | 1–3M |
| Growth Sustainability & Moat | A | 86 | Tirzepatide and semaglutide-adjacent pipeline provide structural moat. 47.4% revenue growth sustainable given GLP-1 market TAM expansion. Sector leadership in obesity/diabetes enduring. | 12M+ |
| Valuation & Safety (Pre-Penalty) | B+ | 73 | PE 55.9x elevated vs. pharma sector median (~18x). Forward PE 27.3x provides relief. High valuation flag active. Justified by growth but limits margin of safety on miss. | 1–3M |
| Penalty Overlay | −6 | −6 | "Strong profitability" flag absent despite high growth raises near-term execution risk. Elevated crowding in obesity theme. Geopolitical exposure (manufacturing, pricing regulation). | 3–6M |
| CONFIDENCE SCORE | A | 84 | Metrics transparency high (PE, EPS, growth rates all disclosed). Data gaps in earnings date & forward guidance limit precision slightly. Live quote quality excellent. | 6–12M |
| Volatility & Drawdown Risk | A− | 80 | Beta 0.50 (well below market 1.0) indicates defensive behavior. YTD decline −0.87% after 59% 52-week run provides technical support. Risk concentrated in regulatory/pipeline execution. | 3–6M |
| Crowding Risk Flag | ELEVATED | 65 | GLP-1 obesity narrative at peak institutional consensus. Valuation premium already embeds significant upside. Downside asymmetry if clinical or regulatory setback occurs. | 1–3M |
Eli Lilly commands a pharma-leading position within the GLP-1 receptor agonist complex, competing with Novo Nordisk (NOVO.CO) and Amgen (AMGN) in the obesity/T2D markets. LLY's valuation (PE 55.9x, forward 27.3x) sits at a premium relative to diversified pharma peers (Merck, AbbVie, Bristol Myers) whose PEs cluster 12–22x, justified by the asymmetric growth profile (128.8% EPS YoY vs. sector median ~8%). The PEG ratio of 0.43 remains attractive on a growth-adjusted basis, though the "strong profitability" flag's absence suggests gross margin headwinds or capacity constraints during the scaling phase. Market cap ($1.15T) places LLY in the top decile of pharma, reflecting institutional dominance and crowding risk in the obesity theme.
LLY Analyst Price Target Forecast - ESEN Analytics
LLY analyst price target: $1270 average (range $850-$1600), based on 29 Wall Street analysts.
Analysis by ESEN Analytics Systems (esenglobalinvest.com), an AI-driven US equity research platform covering 5,000+ US stocks.
LLY Systematic Research
Eli Lilly demonstrates exceptional fundamental momentum, with systematic screening highlighting a 47.44% year-over-year revenue expansion and 128.83% EPS growth—performance metrics substantially outpacing traditional pharmaceutical peers. The company's ROE of 101.31% ranks among the highest in large-cap healthcare, reflecting extraordinary capital efficiency despite the elevated P/B ratio of 38.29 that signals premium market expectations embedded in the valuation.
Profitability metrics reveal structural advantages across the income statement. The gross margin of 82.83% and net margin of 34.99% indicate pricing power and operational leverage, likely driven by recent portfolio additions in diabetes and obesity therapeutics. The beta of 0.51 positions LLY as a defensive holding with lower volatility than broader equity markets, while the current price of $1,148.84 trades approximately 8% below the 52-week high of $1,249.45.
Key strengths include:
- Triple-digit earnings growth substantially exceeding revenue expansion, demonstrating margin improvement
- Return on assets of 22.73% reflecting efficient deployment of the asset base
- Current ratio of 1.58 providing adequate near-term liquidity coverage
Risk factors center on valuation sustainability, with the P/E ratio of 42.57 and P/S multiple of 14.89 demanding continued execution on growth initiatives. The debt-to-equity ratio of 1.6 reflects moderate leverage that requires monitoring during patent cliff transitions.
Relative to Johnson & Johnson, Merck, and Pfizer, the model indicates LLY commands premium multiples justified by superior growth rates, though this positioning creates elevated sensitivity to clinical trial outcomes and competitive therapeutic developments.
Analysis updated monthly based on systematic screening of fundamentals, profitability, growth, and peer positioning.